Association between variant Y402H in age-related macular degeneration (AMD) susceptibility gene CFH and treatment response of AMD: a meta-analysis

To investigate the association between polymorphism rs1061170 (T1277C, Y402H) in age-related macular degeneration (AMD) susceptibility gene Complement Factor H (CFH) and treatment response of neovascular AMD. We performed a literature-based meta-analysis including 10 published association studies in...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2012-08, Vol.7 (8), p.e42464-e42464
Main Authors: Chen, Han, Yu, Ke-Da, Xu, Ge-Zhi
Format: Article
Language:English
Subjects:
Age
Age related diseases
Alleles
Antibodies, Monoclonal, Humanized - pharmacology
Bevacizumab
Biology
Breast cancer
Complement factor H
Complement Factor H - genetics
Confidence intervals
Disease susceptibility
Epidemiology
Ethnicity
Gene polymorphism
Genes
Genetic aspects
Genetic markers
Genetic Markers - genetics
Genetic Predisposition to Disease
Genetic Variation
Genotype & phenotype
Genotypes
Heterogeneity
Homozygote
Humans
Macular degeneration
Macular Degeneration - genetics
Medical ethics
Medical research
Medicine
Meta-analysis
Models, Statistical
Monoclonal antibodies
Odds Ratio
Pathogenesis
Photochemotherapy
Photochemotherapy - methods
Photodynamic therapy
Polymorphism
Polymorphism, Genetic
Ranibizumab
Retina
Statistical analysis
Studies
Subgroups
Systematic review
Targeted cancer therapy
Treatment Outcome
Vascular endothelial growth factor
Vascular Endothelial Growth Factor A - antagonists & inhibitors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To investigate the association between polymorphism rs1061170 (T1277C, Y402H) in age-related macular degeneration (AMD) susceptibility gene Complement Factor H (CFH) and treatment response of neovascular AMD. We performed a literature-based meta-analysis including 10 published association studies involving 1,510 patients. Treatments included anti-VEGF (bevacizumab and ranibizumab) or photodynamic therapy. Summary odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using fixed- and random-effects models. Q-statistic test was used to assess heterogeneity. Polymorphism rs1061170 showed a significant summary OR of 1.68 (95% CI, 1.09 to 2.60; P = 0.020; CC versus TT; random-effects) for treatment response of neovascular AMD with heterogeneity of 0.09. In subgroup analysis, rs1061170 was more likely to be a predictor of response to anti-VEGF therapy (P = 0.011). However, heterozygous TC genotype was not associated with altered treatment response (OR = 1.18, 95% CI, 0.95 to 1.47; P = 0.145; fixed-effects). Influence analysis indicated the robustness of our findings. rs1061170 might be associated with treatment response of neovascular AMD, especially for the anti-VEGF agents. It might be the first meta-analytically confirmed genetic marker predictive for AMD treatment response though a further validation in larger studies is needed.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0042464